LYNN HUNT: Open Payments
NPI 1689805236 · NAPLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,140 in 99 payments from 25 companies in 2025. Trend: 2023 $811 · 2024 $2,483 · 2025 $3,140
Food & beverage: $3,140
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $480 |
| Novo Nordisk Inc | 13 | $347 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $287 |
| Lilly USA, LLC | 7 | $250 |
| Astellas Pharma US Inc | 6 | $217 |
| PFIZER INC. | 11 | $190 |
| Madrigal Pharmaceuticals | 1 | $140 |
| Amgen Inc. | 8 | $137 |
| Neurocrine BioSciences, Inc. | 1 | $137 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $124 |
Products named: CAPLYTA, Ozempic, VRAYLAR, Veozah, QULIPTA, ELIQUIS, REZDIFFRA, INGREZZA.
Industry payments across FL — which companies pay providers there.
